Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises on sale of Emric
Mandate

Vinge advises on sale of Emric

September 01, 2016

Vinge has advised InnKap 4 Partners LP, E. Öhman J:or AB, F Månsson Invest AB and other shareholders in Emric Partners AB in connection with the sale of the company to Tieto.

Emric offers software and services related to credit management and had a turnover of MSEK 185 in 2015. The purchase price is based on an enterprise value valuation of MSEK 300. In addition, the parties have agreed on an earn-out based on Emric’s results during 2017 and 2018.

Vinge’s team consisted of partners Johan Winnerblad and Daniel Rosvall.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024